Multiple Sclerosis

New evidence from a phase 2 clinical trial suggests that ofatumumab—a monoclonal antibody used to treat B-cell–related hematologic malignancies—may be beneficial for the treatment of patients with relapsing forms of multiple sclerosis (MS). In this new study, ofatumumab, given twice by infusion 2 weeks apart, was safe and well tolerated in patients with relapsing-remitting MS (RRMS) and reduced the number of new magnetic resonance imaging (MRI) lesions characteristic of the disease.